Sunday May 12
Onyx Pharmaceuticals Rating Reiterated by TheStreet
's stock had its "hold" rating reaffirmed by research analysts at TheStreet in a report released on Monday, AnalystRatings.Net reports.
Thu May 09, 2013
Onyx Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences
Bank of America Merrill Lynch 2013 Health Care Conference Onyx will present at the Bank of America Merrill Lynch 2013 Health Care Conference on Tuesday, May 14, 2013 at 9:20 a.m. Pacific Time .
Wed May 08, 2013
Onyx Pharmaceuticals Given New $112.00 Price Target at Leerink Swann
A number of other firms have also recently commented on ONXX. Analysts at Barclays Capital raised their price target on shares of Onyx Pharmaceuticals from $93.00 to $98.00 in a research note to investors on Wednesday.
Onyx Pharmaceuticals PT Raised to $110.00
The firm currently has a "buy" rating on the stock. ONXX has been the subject of a number of other recent research reports.
Thu May 02, 2013
The Washington Post
Aveo Fails to Win FDA Panel Backing for Kidney Cancer Drug
Aveo Pharmaceuticals Inc. failed to win the backing of U.S. regulatory advisers for its lead product candidate, a kidney cancer drug, after the panelists questioned whether it was as effective as existing treatments.
Meet the hottest of the red-hot biotechs
Bill Gunderson is a San Diego money manager, financial talk show host, creator of the Best Stocks Now app and editor of the Gunderson Report .
Wed May 01, 2013
Biotechnology Roundup - Aveo Pharmaceuticals Inc. (NASDAQ:AVEO), Onyx ...
Jet Life Penny Stocks provides investors with the Best penny stock alerts on a regular basis.
Tue Apr 30, 2013
The Washington Post
Aveo Kidney Cancer Drug May Need More Study, FDA Staff Says
Aveo Pharmaceuticals Inc.'s lead product candidate, a kidney cancer drug, may need another clinical trial to assess the benefit, U.S. regulators said.
Wed Apr 24, 2013
Onyx Pharmaceuticals PT Raised to $112.00
Several other analysts have also recently commented on the stock. Analysts at JPMorgan Chase raised their price target on shares of Onyx Pharmaceuticals from $100.00 to $105.00 in a research note to investors on Thursday, March 28th.